Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research report sent to investors on Friday morning. The firm issued a sell rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 target price on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Stock Performance

NYSE:SENS opened at $0.32 on Friday. Senseonics has a 52-week low of $0.30 and a 52-week high of $0.75. The business’s fifty day moving average is $0.35 and its 200 day moving average is $0.40. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 3.11. The firm has a market cap of $171.44 million, a price-to-earnings ratio of -2.46 and a beta of 0.79.

Institutional Investors Weigh In On Senseonics

Several hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new position in shares of Senseonics in the 3rd quarter worth about $117,000. Symmetry Partners LLC bought a new position in Senseonics during the third quarter valued at approximately $164,000. Cubist Systematic Strategies LLC raised its stake in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after acquiring an additional 85,501 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Senseonics in the 1st quarter worth approximately $162,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after purchasing an additional 51,000 shares in the last quarter. 12.36% of the stock is currently owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.